Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06298409

Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan®

We will sample intestinal microbiota using a microbiome sampling capsule in patients with Small Intestinal Bacterial Overgrowth (SIBO)

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Silicon Valley Gastroenterology

Mountain View, California, 94040, United States

Location status: Recruiting

Location contact

Jennifer Taufui

CONTACT

[email protected]

About this study

Prospective, open-label, single-arm, non-randomized, multi-center study designed to evaluate the effect of the antibiotic rifaximin on the regional composition of the gut microbiota and metabolic profiles of subjects diagnosed with SIBO, using the CapScan collection capsule.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males or females 18 years of age or older and 80 years of age or younger at the time of the first Screening Visit.
  • ASA Classification 1 or 2.
  • For women of childbearing potential, negative urine pregnancy test within 7 days of Screening Visit.
  • Willingness to use highly effective contraception during the entire study period (e.g.: implants, injectables, oral contraceptives, intra-uterine device or declared abstinence).
  • Subject is fluent in English and understands the study protocol and informed consent and is willing and able to comply with study requirements and sign the informed consent form.
  • Positive for at least one clinical symptom consistent with SIBO.
  • Positive lactulose breath test for SIBO, by Hydrogen (H2) criteria.
  • Prescribed, but has not started, a two-week course of Rifaximin for SIBO.

Exclusion criteria

  • History of any of the following: Prior gastric or esophageal surgery, including lap banding or bariatric surgery, bowel obstruction, gastric outlet obstruction, diverticulitis, inflammatory bowel disease, ileostomy or colostomy, gastric or esophageal cancer, achalasia, esophageal diverticulum, active dysphagia or odynophagia.
  • Actively taking a proton-pump-inhibitor medication within 30 days of enrollment
  • Pregnancy or planned pregnancy within 30 days from Screening Visit, or breast-feeding
  • Any form of active substance abuse or dependence (including drug or alcohol abuse), unstable medical or psychiatric disorder, or any chronic condition susceptible, in the opinion of the investigator, to interfere with the conduct of the study
  • A clinical condition that, in the judgment of the investigator, could potentially pose a health risk to the subject while involved in the study

Treatment and study plan

CapScan collection capsule

Device

The CapScan collection capsule is a single-use device that collects fluids from the gastrointestinal tract for analysis ex-vivo.

Primary outcomes

  1. Sampling of gut microbiota

    Time frame: 56 days

    > 75% of the retrieved CapScan devices to provide at least 3 million metagenomic DNA sequencing reads of gut microbes from the intestinal tract, and at least 900 annotated gut metabolites.

  2. Sampling of gut metabolome

    Time frame: 56 days

    >75% of the retrieved CapScan devices to provide at least 900 annotated gut metabolites.

Secondary outcomes

  1. Effect of rifaximin on gut microbiota

    Time frame: 56 days

    Determine the effect of rifaximin on the regional compositions of the gut microbiota among SIBO patients by assessing the diversity, centroids and distributions of microbial taxa from sequenced CapScan samples of each subject before and after rifaximin at 5 time points.

  2. Effect of rifaximin on gut metabolome

    Time frame: 56 days

    Determine the effect of rifaximin on the regional compositions of the gut metabolites among SIBO patients by assessing the changes to metabolite classes and metabolic pathways as measured by LC/MS-MS analysis of CapScan samples for each subject before and after rifaximin at 5 time points.

Study contacts

Contact information is provided by the study sponsor or research team.

Jennifer Taufui

CONTACT

[email protected]

(650) 988-7530

Sponsors and collaborators

Lead sponsor

Envivo Bio Inc

Industry

Registry information

Official study title

Evaluating the Effect of Rifaximin on the Regional Composition of the Gut Microbiota and Metabolic Profiles of Subjects With SIBO Using the CapScan® Collection Capsule

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Mar 7, 2024
Registry last updated
Jun 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.